Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
Where this comes from
- Record sourced from PubMed, PMID 33452039.
- Also identified by DOI 10.2967/jnumed.120.259226 and PMC identifier 8882898.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). <sup>18</sup>F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of <sup>18</sup>F-DCFPyL PET/CT in determining clinical response to BAT. <b>Methods:</b> Six men with mCRPC receiving BAT were imaged with <sup>18</sup>F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new <sup>18</sup>F-DCFPyL-avid lesion. <b>Results:</b> Three of 6 (50%) patients had progression on <sup>18</sup>F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on <sup>18</sup>F-DCFPyL PET/CT. For the 3 patients who did not have progression on <sup>18</sup>F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. <b>Conclusion:</b> New radiotracer-avid lesions on <sup>18</sup>F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms, Castration-Resistant
- Disease Progression
- Neoplasm Metastasis
- Lysine